Stereotactic Radiosurgery (SRS) is a technique for treating lesions, typically intracranial, most often with a single high dose of ionizing radiation which is enabled by use of a stereotactic device(s) for accurate target localization and patient immobilization. Very rapid fall off of dose to spare normal tissue is achieved by either use of multiple beams, directions, collimation, and/or by exploiting other radiation beam characteristics. While the roots of SRS are often traced back to 1951 and the Swedish Neurosurgeon, Dr. Lars Lekskell (I), it is only recently that "the state of the art" of SRS has experienced its greatest change. Clearly much of this change can be attributed to the very nature of technological evolution witnessed in the areas of computer and/or imaging sciences. However, much can also be attributed to the increased and practical availability of this technology in its various forms (e.g., gamma knife and/or linear accelerator based) with the associated increase in dedicated investigators evaluating, revolutionizing, and defining use of this technology. The very nature of SRS calls for collaboration amongst multiple specialists and/or researchers inclusive of Radiation Oncologists, Medical Physicists, Radiobiologists, Radiologists, Neuro-Oncologists, and Neurosurgeons. Such multi-disciplinary integration can only foster continued evolution, research, and growth within a discipline and is reflected in this issue dedicated to SRS.
The issue begins with a "matter of fact" presentation by Steiber, et al. on the currently available technologies, with focus on the gamma knife and linear accelerator based systems. Both are currently the most commonly used and widely available. This article serves well in allowing the readership to begin formulating its own opinion regarding the various SRS technologies. This is followed by a presentation by the Pittsburgh group led by Flickinger et al. on the radiobiological considerations of tissue response to SRS. It offers a relatively unique perspective to the reader with its detailed inclusion of clinical data in its analyses. Yu and Shephard go on to provide a comprehensive review and discussion of the 'state of the art' in SRS photon beam treatment planning. The issue then presents reviews and new data amongst the most commonly seen clinical cancer-related scenarios addressed by SRS. Sperduto leads off with a review of SRS in the management of brain metastases, inclusive of the latest results of the national Radiation Therapy Oncology Group (RTOG) phase III randomized trial, for which he served as the lead investigator. Patchell and Regine then give the reader a chance to pause on the hotly debated topic of the role of whole brain radiation therapy in conjunction with SRS in patients with brain metastases. Roberge and Souhami then follow with a review of SRS in the management of intracranial gliomas. This presents the results of the RTOG phase III randomized trial for glioblastoma multiforme, for which Souhami was the lead investigator and provides an update and review of ongoing national SRS trials. DiBiase and Chin provide the reader with a comprehensive and clinically useful review of SRS for benign neoplasms. Bourland and Shaw then introduce the reader to the technological advances associated with the evolving role of biological imaging in SRS. Suh and Barnett update the reader on the use of SRS for pediatric brain tumors, inclusive of providing their own experience within the Cleveland Clinic; while St. Clair and Given round out this issue's clinical focus of intracranial SRS by providing a detailed review of SRS associated toxicity. The issues' finale by Timmerman, et al. provides a view into the area likely to be associated with the greatest future growth and evolution of SRS technology, with its expansion beyond the brain and into various extracranial sites.
The contributors and their presentations have done an outstanding job and serve the reader well in providing "the state of the art" of SRS. In addition, this dedicated issue will provide significant insight into the future of SRS technology in cancer research and treatment.
